peoplePerson
Alessandro Gronchi
Sarcoma surgeon who led the ISG-STS 1001 trial of histology-tailored neoadjuvant chemotherapy.
Alessandro Gronchi leads the sarcoma service at INT Milan and chaired ISG-STS 1001 and STRASS, trials that defined neoadjuvant chemotherapy and radiotherapy in high-risk soft-tissue sarcoma.
Role
Chair, Sarcoma Service, Fondazione IRCCS Istituto Nazionale dei Tumori
Specialisms
Sarcoma surgeryRetroperitoneal sarcomaNeoadjuvant chemotherapy
Profiles
| Title | Journal | Year |
|---|---|---|
| Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001) | Lancet Oncology | 2017 |